Certara Investor Presentation Deck

Our end markets are large and growing Biosimulation $2.8B+ Regulatory Science $8.8B+ Market Access $1.5B+ 12% -16% CAGR $13B+ TAM Today CAGR ~16% ~12% ~12% $21B+ 2026 TAM • Drastic need for digital transformation in $212B biopharma R&D market¹ • Industry is in paradigm shift, with biosimulation adoption accelerating and increasing acceptance from regulatory agencies ● Technology and analytics-driven improvements continue to grow exponentially in Life Sciences We use biosimulation and technology throughout R&D to reduce costs and improve outcomes 1. As of 2021 Sources: Grand View Research, SpendEdge © Copyright 2022 Certara, Inc. All rights reserved. 11 CERTARA

View entire presentation